Nalu Bio | Harnessing the power of the endocannabinoid system for a healthier future

The Engine Behind the Innovation: Our ECS Technology Platform

Modern life has created a biological mismatch—our bodies, built for balance, are now overwhelmed by chronic stress, poor diets, and environmental toxins. This imbalance is fueling rising rates of inflammatory, immune, and metabolic diseases.

Nalu Bio is solving this challenge by systematically mapping the endocannabinoid system (ECS), using deep learning to uncover causal relationships between ECS targets and disease pathways.

Our ECS platform designs novel, patentable molecules optimized for drug-like properties, safety and efficacy. This enables the rapid development of a pipeline of targeted, non-addictive therapeutics—built to fully unlock the potential of ECS modulation.

Nalu Bio Technology Differentiation

Nalu Bio is pioneering ECS drug discovery with a platform that integrates four key components to accelerate therapeutic innovation:

KNOWLEDGE
BASE

A proprietary, structured database of ECS receptors, biomarkers, therapeutic targets, and drug-disease associations, integrating omics data, clinical trials, and real-world evidence.

DEEP LEARNING ANALYSIS

Proprietary AI models that analyze our Knowledge Base to identify causal relationships between ECS targets and diseases. Compounds are prioritized based on predicted efficacy, safety, and scalability.

GENERATIVE
AI ENGINE

Our proprietary small language model (SLM) is optimized for molecule creation—generating new, patentable ECS-targeted compounds with ideal drug-like properties, desired binding affinity, including manufacturability.

EXPERIMENTAL
VALIDATION

Lead candidates are synthesized and validated through in vitro screening and in vivo disease-specific models to ensure real-world efficacy.

The pharmaceutical world has seen this before. GLP-1 receptors, once associated only with diabetes, became the foundation of an $80B+ market—expanding into weight loss, cardiovascular health, addiction, and cognition.

The ECS presents a similar, yet largely unexplored opportunity. Its primary receptors, CB1 and CB2, belong to the G Protein-Coupled Receptors (GPCR) family, which accounts for 30-40% of all approved drugs—yet ECS-targeted drugs remain virtually nonexistent.

Mirroring the GLP-1 Market

What’s been missing is a rigorous, AI-driven platform to de-risk and optimize drug discovery.

Why It Matters

Traditional ECS research has relied on natural cannabinoids with poor bioavailability, intoxicating effects, and inconsistent outcomes. Nalu Bio is developing precision-engineered compounds that improve reliability, safety, and efficacy—bringing the GLP-1 playbook to a new therapeutic frontier.